title: Induction of adult-like antibody, Th1, and CTL responses to measles hemagglutinin by early life murine immunization with an attenuated vaccinia-derived NYVAC(K1L) viral vector.
abstract: Although initially developed in adult animals, novel viral vectors expressing recombinant measles antigens must eventually prove their success in the early life setting, where the efficacy of the currently used live-attenuated measles virus vaccine is limited. The immunological requirements for vaccine candidates include the generation of protective antibody responses as well as the induction of Th1 and cytotoxic T lymphocytes (CTL) responses, which is challenging in the neonatal setting. Here, we report that young BALB/c mice immunized with a single dose of a vaccinia-based NYVAC(K1L) vector generate adult-like antihemagglutinin (HA) antibody responses as well as adult-like Th1 and CTL responses. Despite this strong immunogenicity in early life, antibody responses (but not T-cell responses) to a single dose of NYVAC(K1L)-HA remained susceptible to inhibition by preexisting measles antibodies, calling for use of prime-boost strategies. NYVAC(K1L)-HA is the first attenuated live viral vector demonstrated as capable of inducing adult-like antibody, Th1, and CTL responses against measles in an early life murine immunization model, a capacity previously only reported for measles DNA vaccines.
authors: World Health Organization Collaborating Centre for Neonatal Vaccinology, University of Geneva Medical School, Geneva, Switzerland. jiri.kovarik@medicine.unige.ch
authors: J
authors: J
authors: Kovarik
authors: M
authors: M
authors: Gaillard
authors: X
authors: X
authors: Martinez
authors: P
authors: P
authors: Bozzotti
authors: P H
authors: PH
authors: Lambert
authors: T F
authors: TF
authors: Wild
authors: C A
authors: CA
authors: Siegrist
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D000914:Antibodies, Viral / Q000032:analysis; D004195:Disease Models, Animal; D005260:Female; D005822:Genetic Vectors; D006389:Hemagglutinins, Viral / Q000276:immunology*; D006801:Humans; D007117:Immunization, Secondary; D008297:Male; D008457:Measles / Q000276:immunology* / Q000517:prevention & control; D008458:Measles Vaccine / Q000008:administration & dosage; D051379:Mice; D008807:Mice, Inbred BALB C; D018103:Morbillivirus / Q000276:immunology*; D013047:Specific Pathogen-Free Organisms; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D018417:Th1 Cells / Q000276:immunology; D013997:Time Factors; D014613:Vaccines, Attenuated / Q000008:administration & dosage; D014616:Vaccinia virus / Q000235:genetics
chemical_list: D000914:Antibodies, Viral; D006389:Hemagglutinins, Viral; D008458:Measles Vaccine; D014613:Vaccines, Attenuated